Of note, lenvatinib, targeting VEGFR1/2/3, PDGFR, FGFR, KIT, and RET, exhibited promising anti-tumor activity in a phase I clinical trial (LENABC, NCT04656249) involving previously treated patients with CCA. This evidence concerns the gene KIT and cholangiocarcinoma.